Video

Dr. Long on Surgical Advances in NSCLC

Jason M. Long, MD, assistant professor of surgery, Division of Cardiothoracic Surgery, University of North Carolina at Chapel Hill, discusses specific minimally invasive thoracic surgery approaches in lung cancer.

Jason M. Long, MD, assistant professor of surgery, Division of Cardiothoracic Surgery, University of North Carolina at Chapel Hill, discusses specific minimally invasive thoracic surgery approaches in lung cancer.

Generally, video-assisted thoroscopic surgery has been the minimally invasive approach in lung cancer. However, there is a high and steep learning curve. Unless you undergo that training in fellowship, it’s very hard to convert from an open approach to a video-assisted thoracoscopic (VATS) approach in practice, says Long.

Robotic surgery has less of a learning curve than VATS; it’s a little easier to learn, says Long. It offers a better ability to see and get around structures safely. That has been the approach in minimally invasive surgery for the past 5 to 10 years. However, one of the difficulties with robotic surgery is you can’t palpate small lung nodules and navigational bronchoscopy can assist with that.

Related Videos
Alan Tan, MD, genitourinary oncology and melanoma specialist, Vanderbilt-Ingram Cancer Center; associate professor, medicine, Division of Hematology Oncology, Vanderbilt University Medical Center
Zosia Piotrowska, MD, MHS, instructor, Harvard Medical School; medical oncologist, Massachusetts General Hospital
Bartosz Chmielowski, MD
Raza Hoda, MD, FASCP
Armin Ghobadi, MD, professor, medicine, Oncology, Section of Bone Marrow Transplant; clinical director, Center for Gene and Cellular Immunotherapy, Siteman Cancer Center, Washington University
Timothy S. Fenske, MD, MS
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD